Assessing the risk-benefit profile of classical psychedelics : a clinical review of second-wave psychedelic research David Bender & David J. Hellerstein Psychopharmacology (Berl), 2022. Doi : 10.1007/s00213-021-06049-6 Abstract Rationale : A broad reassessment of the potential benefits of psychedelic drugs has led to the initiation of multiple major clinical trials in an effort to advance their status to become FDA-approved medications, as well as local legislative efforts to legalize or decriminalize their use. Objectives : To use recently published data to assess potential risks and benefits of psychedelic drugs as therapeutics, as well as to synthesize what is currently known in order [...]
Lire la suiteHallucinogens in Mental Health : Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine Danilo De Gregorio, Argel Aguilar-Valles, Katrin H. Preller, Boris Dov Heifets, Meghan Hibicke, Jennifer Mitchell, and Gabriella Gobbi The Journal of Neuroscience, 2021, 41 (5), 891–900. Doi :10.1523/JNEUROSCI.1659-20.2020 A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of psychiatric disorders. In the last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine in the treatment of depression. More recently, emerging evidence has pointed out the potential therapeutic properties of psilocybin and LSD, as well as [...]
Lire la suite